|Bid||0.00 x 800|
|Ask||0.00 x 800|
|Day's Range||30.81 - 34.76|
|52 Week Range||12.20 - 70.00|
|Beta (5Y Monthly)||0.10|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug. 05, 2021 - Aug. 09, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||64.67|
Scholar Rock Holding Corporation (SRRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CAMBRIDGE, Mass., Jun 18, 2021--Scholar Rock announced a presentation of results from the TOPAZ Phase 2 trial that evaluated apitegromab in patients with Type 2 and Type 3 SMA at EAN
CAMBRIDGE, Mass., Jun 11, 2021--Scholar Rock today announced an oral presentation of TOPAZ Phase 2 trial results by Dr. Thomas Crawford at the Cure SMA Annual SMA Conference.